Enorama Pharma
Enorama Pharma AB is a Swedish Nasdaq First North–listed pharmaceutical company that develops and sells the NIC-S tobacco-free nicotine pouch brand, a patented nicotine chewing gum for smoking cessation, and the ChewMed® medical chewing gum manufacturing platform, primarily serving US retail and direct-to-consumer nicotine users.
- Company typePublic
- Founded2014
- HeadquartersMalmö, Sweden
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Enorama Pharma does
Enorama Pharma AB is a Swedish pharmaceutical company listed on Nasdaq First North Growth Market (ticker sto:ERMA), headquartered in Stockholm with operational presence in Malmö. The company develops and commercializes consumer-friendly oral nicotine products across three lines: NIC-S, a 100% tobacco-free nicotine pouch brand sold in six flavors and three strengths; a patented nicotine chewing gum for smoking cessation; and ChewMed®, a proprietary platform for manufacturing medical chewing gums using a method the company describes as better suited than traditional techniques for pharmaceutical applications. The European Patent Office granted Enorama's patent on nicotine-containing chewing gum composition and manufacturing method in May 2024.
The company's go-to-market blends direct-to-consumer and B2B channels. NIC-S was launched in the US market in April 2025 and is distributed through 700+ convenience and retail stores across 21 states and an owned US e-commerce storefront, supported by earned media in Convenience Store News and trade-fair exposure at World Tobacco Middle East. On the B2B side, Enorama manufactures private-label nicotine and oral-care products for retailers and operates ChewMed® as a contract-manufacturing platform for medical chewing gum applications. Manufacturing relies on the company's modern chewing gum production technology, while R&D focus is on consumer-adapted nicotine formulations targeting the smoking cessation and tobacco harm-reduction segments.
Enorama's financial position is acute. As of March 2026, parent equity stood at SEK -25,559,465 — less than half of registered share capital of approximately SEK 11.65 million — following an FDA Refuse-to-File decision on the US subsidiary's tobacco product applications. The company has survived 2026 on related-party loans from its largest shareholder, DS Global Pte Limited (~29.81% owner), totaling USD 2 million in November 2025 plus a USD 4 million loan facility in February 2026 at 9% interest with conversion rights. An extraordinary general meeting on April 7, 2026 resolved to continue operations rather than liquidate, with the board committed to restoring equity within eight months. Bengt Jönsson serves as acting CEO.
Enorama Pharma firmographics
Firmographics- Name
- Enorama Pharma
- Legal name
- Enorama Pharma AB
- Website
- https://enorama.se
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Enorama Pharma AB is a Swedish Nasdaq First North–listed pharmaceutical company that develops and sells the NIC-S tobacco-free nicotine pouch brand, a patented nicotine chewing gum for smoking cessation, and the ChewMed® medical chewing gum manufacturing platform, primarily serving US retail and direct-to-consumer nicotine users.
- Ownership category
- akta.pro rank
Enorama Pharma industry classification
Industry- Product category
- Smoking Cessation Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Tobacco, Electronic Cigarette, and Other Smoking Supplies Retailers (459991), Tobacco Product and Electronic Cigarette Merchant Wholesalers (42494)
- SIC
- Pharmaceutical Preparations (2834), Tobacco Products (2100)
- akta.pro industry
- Nicotine Pouches (Tobacco-Free) Manufacturing & BrandsConsumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Tobacco & Nicotine Products Manufacturing & BrandsNicotine Pouch RetailConsumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Tobacco & Nicotine Retail (Cigarettes, Cigars, Smokeless)Smoking Cessation & Nicotine Replacement Therapy (Gum, Patches, Lozenges)Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)Nicotine Replacement Therapy (NRT) Consumer Products Manufacturing & BrandsConsumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Tobacco & Nicotine Products Manufacturing & Brands
Keywords
Where Enorama Pharma is headquartered
LocationHeadquarters
- HQ city
- Malmö
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Enorama Pharma business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Product Sales - NIC-S Brand: Sale of 100% tobacco-free nicotine pouches under the company's own NIC-S brand in 6 flavors and 3 strengths.
- Private Label Products: Development and commercialization of premium products under Private Label arrangements in commercially strong business areas.
- ChewMed Medical Chewing Gum: Manufacturing and sale of medical chewing gums developed with the company's unique technology platform.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Enorama Pharma product offering
Product offeringCore offering
Enorama Pharma manufactures and commercializes nicotine replacement therapy products, including NIC-S nicotine pouches and Nikotintuggummi (nicotine chewing gum) sold to consumers through retail and online channels. The company also operates a proprietary ChewMed platform that enables the production of medical chewing gum for pharmaceutical ingredients, offered to business clients under private-label and licensing arrangements.
Product overview
Enorama Pharma is a Swedish pharmaceutical company listed on Nasdaq First North Growth Market, focusing on the development and commercialization of consumer-friendly oral nicotine products. The portfolio consists of three main offerings: NIC-S (100% tobacco-free nicotine pouches in 6 flavors and 3 strengths), proprietary patented nicotine gum for smoking cessation, and ChewMed® for medical applications using a modern chewing gum technology platform.
Differentiator
Problem solved
Functional benefit
Brands
- NIC-S: 100% tobacco-free nicotine pouches available in 6 flavors and 3 strengths, marketed under own brand
- ChewMed
Products and services
- NIC-S
- Nikotintuggummi
- ChewMed
Quantifiable outcome
- NIC-S available in 700+ US stores across 21 states and online
Companies that use Enorama Pharma
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Enorama Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Enorama Pharma partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
Enorama Pharma competitors and assessment
Company assessmentDirect peers
- Haypp Group: Swedish-based online retailer of nicotine pouches and other smoke-free products. Directly comparable business model combining private label and branded nicotine pouch distribution; significant overlap in European online channels.
- Altria Group (On! / Helix): Altria markets On! and Helix nicotine pouch brands in the US, directly competing with NIC-S in convenience and tobacco retail channels. Comparable product (tobacco-free pouches), target consumer, and distribution model.
- Philip Morris International (Zyn): Philip Morris International owns Zyn, the global market-leading tobacco-free nicotine pouch brand. Directly competes with Enorama's NIC-S in the same product category, same smoke-free oral nicotine format, and overlapping retail channels in the US and Europe.
- Japan Tobacco International (Nordic Spirit): JT International's Nordic Spirit competes directly with NIC-S in the European and US nicotine pouch market with similar tobacco-free formulations. Comparable product positioning targeting smoke-free adult consumers.
- British American Tobacco (Velo): BAT's Velo (formerly Lyft) is a major nicotine pouch brand competing in the same product category as NIC-S across US and European retail. Comparable product format, flavors, strengths, and consumer segments.
Broad incumbents
- Perrigo Company: Perrigo manufactures private label and store-brand nicotine replacement therapy gum, directly comparable to Enorama's private label NRT offerings. Both target the value-tier of smoking cessation.
- Swedish Match (legacy snus portfolio): Swedish Match (now part of Philip Morris) historically dominated Swedish-style smokeless tobacco and now leads in pouches. Comparable in heritage, geographic origin, and product category, though at vastly larger scale.
- Johnson & Johnson (Nicorette): Johnson & Johnson's Nicorette is the global market-leading NRT gum brand, directly competing with Enorama's nicotine chewing gum in smoking cessation category across pharmacy and retail.
- Haleon (Nicotinell): Haleon owns Nicotinell, a leading OTC nicotine replacement therapy gum brand. Direct competitor in Enorama's nicotine gum business, with broader portfolio and pharmacy distribution muscle.
Emerging players
- Niconovum: Niconovum develops OTC nicotine replacement therapy products including mouth sprays and pouches, with overlapping target use cases in smoking cessation. Comparable smaller-scale NRT innovator with similar focus on alternative delivery formats.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Enorama Pharma social profiles
Digital presenceEnorama Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Enorama Pharma leadership team
Management profileNumber of profiles
Profiles8 records
Enorama Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Enorama Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Enorama Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Enorama Pharma
What does Enorama Pharma do?
Enorama Pharma manufactures and commercializes nicotine replacement therapy products, including NIC-S nicotine pouches and Nikotintuggummi (nicotine chewing gum) sold to consumers through retail and online channels. The company also operates a proprietary ChewMed platform that enables the production of medical chewing gum for pharmaceutical ingredients, offered to business clients under private-label and licensing arrangements.
Is Enorama Pharma a public or private company?
Enorama Pharma is a public company. It is classified as public and is currently operating.
When was Enorama Pharma founded?
Enorama Pharma was founded in 2014. It employs 1 to 10 people.
Where is Enorama Pharma based?
Enorama Pharma is headquartered in Malmö, Sweden, in the Europe region.
How does Enorama Pharma make money?
Three revenue lines are on record. Product Sales - NIC-S Brand is the primary driver. The others are private Label Products and chewMed Medical Chewing Gum.
Who are Enorama Pharma's main competitors?
Direct peers on record are Haypp Group, Altria Group (On! / Helix), Philip Morris International (Zyn), Japan Tobacco International (Nordic Spirit) and British American Tobacco (Velo). Broad incumbents are Perrigo Company, Swedish Match (legacy snus portfolio), Johnson & Johnson (Nicorette) and Haleon (Nicotinell). Niconovum is listed as an emerging player.
Does Enorama Pharma have an API?
No public API is recorded for Enorama Pharma.
What industry is Enorama Pharma in?
Enorama Pharma's product category is Smoking Cessation Pharmaceuticals. Its primary akta.pro industry code is CRADAJAI, Nicotine Pouches (Tobacco-Free) Manufacturing & Brands, with a secondary code of CRANADAD, Nicotine Pouch Retail. Its NAICS code is 32541 and its SIC code is 2834.